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Abstract
Nanomedicine has seen a significant increase in research on stimuli-responsive activatable nanoprobes for
tumor-specific delivery and diagnosis. The tumor microenvironment has particular characteristics that can be
exploited to implement therapeutic strategies based on disparities between normal tissues and tumor tissues,
including differences in pH, oxygenation, enzymatic expression, gene activation/inactivation, and vasculature.
The nanocarriers of activatable nanoparticles maintain their structure while circulating in the body and, upon
reaching the tumor site, are altered by unique tumoral stimuli, leading to the release of a drug or other agent.
This review demonstrates the latest achievements in the use of internal stimuli-responsive, activatable nanoparticles
with respect to unique design strategies and applications.
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Background
Nanotechnology is a multidisciplinary research field
offering exciting possibilities to revolutionize the field
of biomedicine through transformative diagnostic and
therapeutic tools [1–3]. The past decade has witnessed
the successful introduction of a plethora of nanoparticles
for cancer diagnosis, imaging, and treatment [4–7]. Nano-
particles have been fabricated with unique physical and
chemical properties originating from myriad materials
such as organic compounds, inorganic compounds, and
hybrid compounds [2, 8, 9].
The early diagnosis of the pathological state of tumors is
the mainstay of successful cancer treatment and personal-
ized therapy [10]. Multifunctional nanoparticles, which
provide both diagnostic and therapeutic features, have
attracted great attention by providing early visualization of
tumors and effective delivery of therapeutic agents with
minimal side effects [11–15]. Nanoparticles engineered to
carry a large payload of drug entities and target specific
tumor sites represent an alternative to small-molecule im-
aging agents or drugs [5]. Targeting can be achieved
through antibodies, aptamers, small tumor-specific
peptides, polymers, and other molecules. Although target-
ing factors provide high cancer-cell specificity by binding
to specific tumor epitopes, more efficient delivery systems
are needed to control the release of the therapeutic cargo
(drug, gene, or protein) from the nanocarrier. Such
delivery systems must interact minimally with the bio-
logical components of the nanoparticle and must pre-
vent the release of the cargo during circulation in the
blood stream [16–19].
Irrespective of the presence of highly specific ligands,
the heterogeneity of cancer-specific biomarkers among
cancer types and organ sites makes it a challenging
task to establish a foolproof strategy for cancer diagnosis
[6, 15, 20]. To overcome that challenge, many recent
studies have established the presence of biomarkers in the
tumor microenvironment that are more consistent across
a range of cancer types. The metabolism of cancer cells
is very distinctive. Angiogenesis, dysregulated glycolysis
leading to acidic pH and chronic oxidative stress, pro-
liferative signaling, and the evasion of growth suppres-
sors affecting enzymes and small molecules such as
miRNA/DNA are all hallmarks of cancer. The targeting
of those tumor hallmarks provides promising strategies
for broad tumor detection [2, 15].
Activatable nanoparticles offer a platform to overcome
the disadvantages of traditional tumor-targeting tech-
niques by remaining intact before reaching the target.
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The on-demand activation of nanocarriers, which allows
the efficient delivery of therapeutic agents with excellent
dosage control, is becoming feasible. That approach re-
quires the careful fabrication of nanoconstructs that are
capable of undergoing specific, stimulus-induced changes
such as conformational changes, hydrolytic cleavage, or
specific protonation. Stimuli-responsive nanoconstructs can
be transformed from a passive form to an active form in re-
sponse to various exogenous or endogenous stimuli. Ex-
ogenous stimuli-responsive nanoconstructs take advantage
of externally applied stimuli and include thermoresponsive
systems, magnetic-responsive systems, ultrasound-triggered
systems, light-triggered systems, and electroresponsive sys-
tems. Endogenous stimuli-responsive systems take advan-
tage of the tumor microenvironment [15]. For example, at
the cellular level, pH variations can be exploited to control
drug release in late endosomes or lysosomes or in the
generally low pH environment of cancer-specific sites.
Also, the glutathione concentration varies between the
extracellular environment and the intracellular environ-
ment and between tumor tissues and healthy tissues,
potentially providing a way to attain redox sensitivity
via the cleavage of disulfide bonds [21–23].
In this review, we discuss the most important progress
made recently in nanoparticle synthesis. We also describe
recent approaches that attempt to overcome the draw-
backs of endogenous stimuli-responsive nanosystems for
drug or gene delivery, with a particular emphasis on
tumor treatment.
Types of nanoparticles
Inorganic
Table 1 shows the various types of nanoparticles
currently used in biomedical research. Different classes
of inorganic nanoparticles have recently gained much
attention as potential diagnostic and therapeutic sys-
tems. Gold, iron oxide, silica, quantum dots, and other
molecules have been investigated for the treatment and
detection of diseases [24–30]. Super paramagnetic iron
oxide nanoparticles (SPIONS) are probably the most
explored nanoparticles for biomedical applications.
Because of their innate magnetic properties, nanosized
SPIONS are useful as contrast agents in magnetic reso-
nance (MR) imaging for cancer diagnosis and as hyper-
thermia agents for cancer therapy. For example, Jang et
al. [27] synthesized iron oxide nanoparticles with very
high magnetism achieved by Zn2+ doping. Compared
with conventional agents, the iron oxide nanoparticles
provide eight to 14 times higher R2 values when used
as MR contrast agents and four times greater specific
loss power (SLP) values when used as hyperthermia
agents (Fig. 1) [27]. Magnetic nanoparticles have also
been utilized for cell separation, stem cell labeling, drug
delivery, and magnetofection [31].
Noble metal (gold, silver, and platinum) nanoparticles
have unique surface plasmon resonance due to their
nanoparticle-sized photon confinement [32]. Among
them, gold nanoparticles are the most extensively studied,
because their unique phonons make them advantageous
for optical and photothermal applications. Several re-
searchers have performed extensive studies to precisely
control and tune the optical properties of gold nanostruc-
tures by changing the size, shape, and structure of the
nanostructures [33–35].
Quantum dots are another example of inorganic nano-
particles that have emerged as versatile tools for biomed-
ical imaging [11]. They are composed of atoms from
groups II–VI or III–V of the periodic table. Quantum
dots have unique optical and electrical properties due to
quantum confinement effects. Recent studies have ap-
plied quantum dots in DNA hybridization, immunology,
receptor-mediated endocytosis, in vitro and in vivo
fluorescence imaging, multiplexed optical coding, and
the high-throughput analysis of genes and proteins.
Silica nanoparticles are another important class of
inorganic nanoparticles [29, 36]. Although silica nano-
particles do not have any special properties due to their
sub-micrometer size, their structure can be tuned to
control their size, shape, and porosity along with the
presence of well-established siloxane chemistry for sur-
face modifications. Those characteristics render silica
nanoparticles suitable for diagnostic and therapeutic
applications. Recently, Lu et al. [29] were able to sup-
press tumor growth in a human xenograft mouse model
using mesoporous silica nanoparticles (MSNs) to deliver
anticancer drugs [29]. In that work, the authors incorpo-
rated fluorescein isothiocyanate, an optical imaging
agent, and the anticancer drug camptothecin (CPT) into
the nanoparticles. As shown in Fig. 2, the CPT-loaded
Table 1 Types of nanoparticles
Type Examples Reference
Inorganic Metal Oxide MFe2O4
(M = Fe, Mn, Co, Zn),
MnxOy (1 ≤ x ≤ 3, 1 ≤ y ≤ 4),
ZnO
Ref. [27, 31, 53]
Noble Metal Au, Ag, Pt Ref. [32, 33]
Quantum Dots CdSe, ZnSe, ZnS, ZnO Ref. [11]
Silica Mesoporous Silica, SiO2 Ref. [29, 36]
Organic Polymer Based Polymersome, Micelle Ref. [37]
Polysaccharide
Based
Chitosan, Hyaluronic acid Ref. [41]
Lipid Liposome, Cholesterol Ref. [42]
Peptide or Protein
Nucleic Acid
siRNA, DNA Ref. [43]
Hybrid Inorganic/Organic
Core/Shell
Ref. [44]
Organic/Inorganic
Core/Shell
Ref. [30]
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Fig. 1 a TEM image of 15-nm (Zn0.4Fe0.6)Fe2O4 nanoparticles. b SLP values for (Zn0.4 Mn0.6)Fe2O4 and Feridex in a 500 kHz AC magnetic field with
an amplitude of 3.7kAm-1. c Percentage of HeLa cells killed after treatment with (Zn0.4Mn0.6)Fe2O4 nanoparticles or Feridex and the subsequent
application of an AC magnetic field for 10 min. d Fluorescence microscopy images of AC magnetic field applied HeLa cells treated with i)
(Zn0.4Mn0.6)Fe2O4 nanoparticles or ii) Feridex. Calcein staining indicates live cells with green fluorescence. Reproduced with permission from ref.
27; Copyright 2009 Wiley-VCH
Fig. 2 a Characterization of fluorescent mesoporous silica nanoparticles (FMSNs). SEM image of FMSNs and photograph showing bright-green
photoluminescence from porous silicon nanoparticles under UV/Vis light. b Biodistribution of FMSNs in mice with xenograft tumors. Nude mice
bearing subcutaneous human breast tumors were injected via the tail vein with FMSNs. Four hours later, the mice were anesthetized and analyzed
with a Maestro 2 in vivo imaging system that produced green fluorescence images. The yellow arrows show the subcutaneous tumors. c Antitumor
effects in mice of FMSNs loaded with Camptothecin (CPT). Animals were injected with either saline solution as a control, CPT, FMSNs without loading
(FMSN), FMSNs loaded with CPT (FMSN/CPT), or F-FMSNs loaded with CPT (Folic acid-FMSN/CPT) twice per week until the end of the experiment
(68 days). The average tumor volumes are shown as means ± SD. *p< 0.05; **p< 0.01. Reproduced with permission from ref. 29; Copyright 2010 Wiley-VCH
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MSNs demonstrated excellent in vivo therapeutic efficacy
in a xenograft model of MCF-7 human breast cancer cells.
Organic nanoparticles
Organic nanoparticles are highly stable in biological
fluids. They can be grouped into four major types:
lipids, polysaccharides, peptides/proteins, and syn-
thetic polymers. Polymeric nanoparticles are by far the
most studied of the organic nanoparticles. A variety of
synthetic polymers including polylactic acid (PLA),
poly(lactic-co-glycolic) acid (PLGA), polyethylene gly-
col (PEG), and polyethyleneimine (PEI) have been uti-
lized in nanoformulations that arrange them into
polymer micelles, polymerosomes, polymer conjugates, or
polymeric nanoparticles. Advancements in polymerization
chemistry and careful control over targeting properties
have enabled the engineering of multifunctional polymeric
nanoparticles. For example, Farokhzad et al. [37] reported
complete tumor reduction in a 109-day study in which
animals were given a single intratumoral injection of
docetaxel (dtxl)-encapsulated PLGA-b-PEG copolymer
functionalized with RNA aptamers (Fig. 3) [38–40]. Some
polymeric nanoparticles also exhibit electronic, opto-
electronic, or photoluminescent behavior. Polyaniline,
polypyrrole, polyacetylene, and their derivatives have been
widely studied for their conductive properties, while
polythiophenes, polyfluorenes, and poly (p-phenylene
vinylene) have been explored for their electro-optical
properties [37].
Among the natural polymers, polysaccharides are the
type most often studied for drug delivery. Chitosan nano-
particles are the polymers of choice for theragnostic appli-
cations. Park et al. [41] modified water-soluble glycol
chitosan derivatives with cholanic acid to form tumor-
targeting, chitosan-based nanoparticles. The high molecu-
lar weight chitosan nanoparticles showed enhanced tumor
targeting due to their high in vivo stability (Fig. 4) [41].
Lipid-based nanocarriers play a major role in cancer
therapy [42]. Nanocarriers, such as liposomes, lipid mi-
celles, solid-lipid nanoparticles, nanosuspensions, and
nanoemulsions, are commonly made of lipid-based ma-
terials, such as cholesterol, phosphatidylcholine, and
1,2-disteardyl-sn-glycero-3-phosphoethanolamine-N-[ami-
no(polyethylene glycol)-2000] (DSPE-PEG 2000). Lipo-
somes are the lipid-based nanoparticles that have been
explored the most for cancer therapies. Liposomes are col-
loidal vesicles with single or multiple bilayered membrane
structures. They are biodegradable and biocompatible and
can encapsulate hydrophilic agents in their aqueous core
and contain hydrophobic agents within their bilayers.
Many clinical studies have shown the successful loading of
hydrophobic drugs such as paclitaxel and doxorubicin into
liposomes for cancer therapy [6].
A recent example of a protein-based nanosystem is
Abraxane [43], which was approved by the FDA in 2005
and is now in clinical use. Abraxane is an albumin-bound
paclitaxel nanoparticle produced in a high-pressure
homogenizer. The drug particle is stabilized by human
Fig. 3 a Scheme and SEM image of Dtxl-encapsulated NPs. b The comparative efficacy study of single intratumoral injection (day 0) of saline,
PEGylated PLGA NP without drug (NP), emulsified Dtxl (Dtxl), Dtxl-encapsulated NPs (Dtxl-NP), or Dtxl-encapsulated NP-Apt bioconjugates (Dtxl-NP-Apt).
A representative mouse at the end point (>109 days) for each group is shown (Left) alongside images of excised tumors (Right). Black arrows indicate the
position of the implanted tumor on each mouse. Reproduced with permission from ref. 40; Copyright 2006 PNAS
Kang et al. Journal of Biological Engineering  (2017) 11:13 Page 4 of 12
serum albumin and has an average size of 130 nm, which
prevents any risk of capillary obstruction. Preclinical trials
conducted in athymic mice with human breast cancer dem-
onstrated that Abraxane has increased antitumor activity
and greater penetration into tumor cells compared with an
equal dose of standard paclitaxel. A phase I trial confirmed
that the maximum tolerated dose of Abraxane is 70%
higher than that of the Cremophor EL® paclitaxel formula-
tion. A phase II trial confirmed that Abraxane has antitu-
mor activity in patients with metastatic breast cancer. A
phase III trial confirmed the superiority of Abraxane over
standard paclitaxel in terms of both the overall response
rate and the time to tumor progression.
Hybrid nanocomposites
The development of hybrid nanocomposites, which com-
bine organic and inorganic components, is intended to pro-
duce composite materials that retain the beneficial features
of both organic compounds and inorganic compounds.
Hybrid nanoparticles can be synthesized either by in-
corporating inorganic particles into a polymer matrix
or by forming core/shell structures. Inorganic/organic
core/shell structures combine a metal, semiconductor,
metal oxide, or silica core with an organic/polymeric
shell, which can save the metal core from oxidation and
also increase biocompatibility. PEG, dextran, and chito-
san have been studied extensively for the coating of
various metal cores to improve biocompatibility and in-
crease the number of applications for a single compo-
nent. For example, Lim et al. [44] developed a
multimodal nanoprobe using the amphiphilic polymer
pyrenyl-PEG and superparamagnetic MnFe2O4 nano-
crystals. The fluorescent magnetic nanoprobes were
biocompatible and had excellent MR sensitivity and op-
tical imaging capabilities [44].
Organic/inorganic core/shell nanoparticles have a
polymer core and an inorganic shell. A metal oxide shell
over a polymer can provide increased strength and abra-
sion resistance. Such systems are also used to synthesize
inorganic, hollow nanoparticles [30].
Types of stimulus response in the tumor
microenvironment
The complexity and heterogeneity of cancer cells re-
quires such cells to adapt and evolve aggressively, indu-
cing the expression of key components of angiogenesis,
hypoxia response, and glycolytic switching [15]. Those
characteristics incite metabolic alterations that can
Fig. 4 a Representative structure of glycol chitosan nanoparticles. b TEM, photograph, and near-infrared (NIR) fluorescence images of Cy5.5-labeled
glycol chitosan nanoparticles. Reproduced with permission from ref. 41; Copyright 2007 ScienceDirect
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change the pH [45, 46], miRNA and gene expression
[47–51], and redox potential [52–61] of the tumor
microenvironment. Table 2 shows the different types of
internal stimuli present in the tumor microenvironment
and the corresponding response materials to control the
activation and behavior of nanostructures. Progress in
the understanding of tumors at the molecular level and
in the control of materials at the nanometer scale has
allowed the development of new investigative tools for
cancer therapy. For efficient cancer therapy, it is impera-
tive that drugs or genes are delivered to the vicinity of the
tumor without being degraded. Many researchers are de-
veloping engineered, stimuli-responsive, multifunctional
nanoparticles that respond to changes in pH, redox po-
tential, or enzyme activity for a variety of applications
such as biomedical imaging, drug or gene delivery, and
biosensing [6].
pH
Irrespective of the cancer type, the Warburg effect, or
abnormally high rate of aerobic glycolysis, is a recog-
nized hallmark of cancer and is perceived as a major
biochemical alteration associated with malignant trans-
formation [21, 22]. Otto H. Warburg observed that liver
cancer cells display increased glycolytic activity in the
presence of oxygen compared with normal cells. Instead
of using pyruvate, cancer cells ferment glucose into lac-
tic acid to generate ATP, even in the presence of oxygen.
Unlike normal cells, cancer cells produce approximately
60% of their ATP from glycolysis. Therefore, cancer cells
and tissues have an acidic pH. Various researchers have
used that metabolic difference between normal cells and
cancer cells as a biochemical basis to develop anticancer
therapeutic and imaging strategies [23]. Wang et al. [46]
demonstrated a signal amplification strategy using ultra
pH-sensitive (UPS) fluorescent nanoprobes [46]. UPS
nanoparticles are composed of three components: a UPS
core that provides a sharp pH transition (at pH 6.5 ~ 6.8);
fluorophores that provide homo-FRET quenching; and a
Arg-Gly-Asp that provides a targeting moiety. As shown
in Fig. 5, UPS nanoparticles activate strongly upon suitable
changes in the physiological pH, amplifying the signal of
the tumor microenvironment. The endosomal/lysosomal
pH, which is 1.4–2.4 units lower than the physiological
pH, can be exploited by pH-sensitive nanocarriers encap-
sulating drugs, genes, or contrast agents. Such nanocar-
riers bind to the endosomal membrane after endocytosis
and eventually release their payload into the cytoplasm
when they become destabilized by the low pH. For ex-
ample, Kim et al. [45] designed an endosomal pH-
triggered drug-delivery system [45]. The objective was to
avoid premature drug release in the extracellular environ-
ment and also to avoid toxicity due to the leakage of
digestive lysosomal enzymes. They used a mixed mi-
celle approach to design a doxorubicin-loaded micelle
composed of a pH-sensitive core [poly(histidine (His)-
co-phenylalanine (Phe))-b-polyPEG)], which is stable at
pH 7 but unstable at pH 6.5, and another destabilization
pH-adjusting blending polymer [poly(L-lactic acid) (PLLA)-
b-PEG-folate], which causes destabilization at pH 6. The
activation at endosomal pH combined with folate receptor-
mediated endocytosis effectively accelerated doxorubicin
release at pH 6.0, resulting in the efficient killing of cancer
cells in vitro. Choi et al. demonstrated another applica-
tion of a pH-based system in their investigation of the
endosomal-lysosomal system. They developed a polya-
niline (PANI)-based organic quencher for intracellular
compartmental trafficking by adsorbing multi core-
shell Fe3O4/MnO/Silica/PANI nanoparticles with Cy3
and Cy7 fluorophores to efficiently quench the emeraldine-
base and emeraldine-salt forms of PANI, respectively.
Changes in the pH throughout the endosomal-lysosomal
pathway led to reversals in the transition states of the
emeraldine base and the emeraldine salt, quenching the
Cy3 emission and activating the Cy7 emission.
Enzyme
Enzymes are key components in all biological processes.
The dysregulation of enzyme activity has been observed in
many pathological conditions, rendering the detection of
enzyme expression a powerful tool for diagnosis [62, 63].
The exceptional efficiency of enzymes in the selective
recognition of their substrates makes them a sophisticated
tool for producing biologically inspired chemical reactions.
That has led to a growing interest in the development of
bioresponsive nanoparticle systems, including polymeric
nanoparticles, liposomes, metal and semiconducting na-
noparticles, and silica nanoparticles, that respond to the
catalytic activity of enzymes. Nanoparticles can be rendered
enzyme-responsive by the inclusion of moieties that can ei-
ther be cleaved upon recognition by a biocatalyst or be
transformed upon catalytic action by an enzyme [64].
Cancer-associated proteases, esterases, phospholipases, and
Table 2 Types of stimulus responses in the tumor
microenvironment
Stimulus Response materials Reference
pH poly(histidine-co-phenylalanine),
2-(diisopropyl amino) ethyl
methacrylate
Ref. [45, 46]
Enzyme MT1-MMP, MMP7, secretory
phospholipase A2
Ref. [62, 63, 67]
Hypoxia and
oxidative stress
4-nitrobenzyl group
(hypoxic trigger), o-hydroxyl
E-cinnamic ester (photo-activated
group), MnO (glutathione),
quaternized chlormethine (H2O2)
Ref. [52–61]
Nucleic acid
based
molecular beacon Ref. [47–51]
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oxidoreductases are upregulated in tumors and have been
utilized to develop enzyme-responsive nanosystems. For ex-
ample, phospholipase A2 is upregulated in various tumors,
including those of the prostate. Enzyme-responsive nano-
systems have been explored recently in the search for acti-
vatable liposomal drug-delivery systems. Linderoth et al.
[65] developed a novel drug-delivery system that combines
lipid-based prodrugs formulated as liposomes with overex-
pressed secretory phospholipase A2 (sPLA2) as a trigger for
activation [65]. As a model drug, they used capsaicin pro-
drug 8, which forms a uniform bilayer of vesicles directly
upon dispersion in a buffer. The ester group at the Sn-2
position of glycerophospholipids is hydrolyzed by sPLA2 ,
so the researchers synthesized a glycerophospholipid de-
rivative with the drug at the Sn-1 position. When the ester
group at the Sn-2 position was hydrolyzed, an OH group
was released, which reacted with the ester group at the Sn-1
position to form a lactone and thereby release the drug.
Proteases are the most commonly exploited enzymes.
Matrix-metalloproteases (MMPs) play an essential role
in tumor-cell invasion into connective tissue [66].
Researchers have utilized that role to detect invasive
cancer cells by comparing the MMPs of malignant cells
with the secreted, soluble MMPs of normal cells. Park et
al. [67] developed an enzyme-activatable, bimodal
imaging probe for the simultaneous determination of the
expression and proteolytic activity of the MT1-MMP
present on the surface of invasive cancer cells. They
used an activatable fluorogenic peptide (ActFP) that acts
as both a targeting moiety and a proteolytic site for
MT1-MMP [67]. ActFPs provide fluorogenic activity by
combining an NIR dye with a quencher to induce a
FRET effect. Upon enzymatic cleavage of the MMP
ligand, the NIR dye fluoresces in the cytoplasm. ActFP
probes can also be conjugated with magnetic nanoparti-
cles for combined fluorescence and MR imaging (Fig. 6).
Fig. 5 a Schematic of the imaging of the tumor microenvironment using ultra pH-sensitive (UPS) nanoprobes. The UPS nanoprobes stay ‘OFF’ at
pH 7.4 during blood circulation. After reaching the tumor, the UPS nanoprobes are turned ‘ON’ by the acidic extracellular pHe (6.5–6.8) in the tumor
milieu or in endocytic organelles (pHi 5.0–6.0) in the tumorous endothelial cells after receptor-mediated endocytosis. b Structural composition of the
two types of nanoprobe, UPSe and UPSi, with pH transitions at pH 6.9 and pH 6.2, respectively. c Normalized fluorescence intensity as a function of pH
for UPSe and UPSi nanoprobes. At high pH (e.g., 7.4), both probes stay silent. At pH below the transition levels (i.e., pH 6.9 and 6.2), the nanoprobes can
be activated as a result of micelle dissociation. d Fluorescent images of UPSe–Cy5.5 nanoprobe solution in different pH buffers (λex/ λem = 675/710 nm).
e Transmission electron micrographs of UPSe nanoprobes at pH 7.4 and pH 6.7 (polymer concentration = 1 mg/ml; scale bars = 100 nm). Reproduced
with permission from ref. 46; Copyright 2014 Macmillan Publishers
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Polymeric nanoparticles are the most widely used nano-
platforms for the development of enzyme-responsive sys-
tems. [66] Chemotherapeutic drugs, proteins, genes, and
siRNAs have been delivered using enzyme-responsive
polymeric nanoparticles. In a recent study, Li et al. [66]
developed a smart polymeric nanoparticle containing a
positively charged dimethylaminoethyl (DMAEMA)
corona to package siRNA and also act as a pH-responsive
core. They linked the corona to a PEG layer via an MMP-7
cleavage peptide, which shielded the nanoparticles from
nonspecific cell interactions. Once the PEG layer was
cleaved in an MMP-7-rich environment, the nanoparticles
became positively charged, and their rate of internalization
increased 2.5-fold because of the negative-positive charge
interactions. The pH change following internalization fur-
ther disrupted the corona, leading to siRNA escape from
the endolysosomal pathways.
Hypoxia and oxidative stress
Tumors have inadequate vasculature and therefore
rapidly exhaust their blood supply, leading to glucose
deprivation and hypoxia. Glucose deprivation prevents
the decomposition of endogenous oxygen radicals, caus-
ing oxidative stress. Hypoxia and oxidative stress are
both present in tumor cells and are interlinked. Angio-
genesis within the tumor tissue causes periods of hypo-
xia due to the uncontrolled blood flow. Hypoxia is
known to promote aggressive tumor phenotypes and
causes resistance to chemotherapy and radiotherapy.
Recently, many studies have applied a hypoxia-activated
strategy to release prodrugs, imaging agents, and other
functional molecules within tumor cells. Feng at al.
[60] developed a modified gemcitabine (GMC)-based
pro-prodrug (GMC-CAE-NO2) with an o-hydroxyl E-
cinnamic ester photo-activated group (CAE) and a
nitro-benzyl group, which could not be reduced under
normal oxygen conditions [61]. Under hypoxic condi-
tions, the GMC-CAE-NO2 was converted to the prodrug
GMC-CAE. Subsequently upon UV exposure, alteration of
the prodrug led to the formation of fluorescent dye and
GMC release. The rate of GMC release increased with
decreasing O2 concentration.
Reactive oxygen species (ROS); including hydrogen
peroxide (H2O2), hypochlorous acid (HOCl), superoxide
(O2
-), singlet oxygen (1O2), and hydroxyl radical (OH
-);
are abundant in cancer cells. The overproduction of
ROS leads to redox imbalance and cellular damage. Li
et al. [55] developed chlormethine (Chl), an H2O2-
sensitive quaternized prodrug with an eight-member
cyclic boronate ester that could be triggered in the pres-
ence of H2O2 [55]. They covalently linked the prodrug to
poly(fluorene-co-phenylene; PFP) side chains, creating
PFP-Chl, which successfully released the Chl within
cancer cells and inhibited cell growth. In another study,
Chen at al. [58] developed H2O2-activatable and O2-
evolving photodynamic therapy (PDT) nanoparticles
(HAOP NPs). They encapsulated methylene blue (pho-
tosensitizer) and catalase (O2-evolving agent) in the
aqueous core of a PLGA shell and doped the bilayer of
the shell with black-hole quencher-3 (BHQ-3). They
further modified the surface of the particles with
c(RGDFK), a tumor-targeting peptide. The HAOP NPs
Fig. 6 a The dual imaging process of activatable magnetic nanoprobes (magnetic nanocrystals conjugated with activatable fluorogenic peptides,
MNC-ActFP) for i) molecular detection of MT1-MMP anchored on invasive cancer cells by MR imaging and ii) sensitive recognition of the proteolytic
activity of MT1-MMP by fluorescence imaging. Q = quencher, F = fluorescence dye. b In vivo MR (Upper) and NIR fluorescence (Lower) images of
tumor-bearing mice at different time points after intravenous injection of MNC-ActFP. Red arrowheads in the MR images indicate the signal-enhanced
sites of the tumor. c ΔR2/R2 nontreatment (line scatter) and NIR fluorescence intensity (bar graphs). d NIR fluorescence images (upper) and their intensity
graph (lower) for excised tumors from tumor-bearing mice 1 h after intravenous injection of MNC-ActFP, MNC-ScrFP, or MNC-ActFP plus
inhibitor. Reproduced with permission from ref. 67; Copyright 2011 Wiley-VCH
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were selectively taken up by αvβ3 integrin-rich tumor
cells, followed by H2O2 penetration into the core, ca-
talysis by catalase, and O2 generation, causing the rup-
ture of the polymer shell. Thus, the nanoparticles
allowed the controlled release of 1O2 within tumor
cells, providing high-efficiency in vivo PDT while also
overcoming hypoxia-induced drug resistance.
Glutathione (GSH) plays a major role in protecting cells
against oxidative stress by undergoing a conversion from
reduced GSH to oxidized GSSG [53]. The concentration of
GSH is extremely high in tumor cells, making it an ideal
biomarker. Yang et al. [53] synthesized GSH-responsive,
MSHs for controlled drug release. As shown in Fig. 7, they
reduced KMnO4 to generate an MnO2 nanolayer over
MSHs loaded with doxorubicin. In the presence of GSH,
the MnO2 nanostructure dissociated, leading to the forma-
tion of Mn2+ and the release of doxorubicin through the
mesopores. In other research, Kim et al. developed activa-
table T1 and T2 dual-mode MR imaging agents to avoid
MR contrast enhancement upon nonspecific interactions.
They synthesized an Fe3O4 core/Mn3O4 shell nanosystem
in which the Mn3O4 shell shielded the iron oxide against
water protons and thus inhibited T2 contrast enhance-
ment. The Mn3O4 shell also acted as a redox switch that
activates in the presence of glutathione, releasing Mn3+
ions (to provide T1 contrast enhancement) and allowing
the iron oxide core to interact with water protons (to
provide T2 contrast enhancement). The researchers
demonstrated effective passive tumor targeting for T1 and
T2 weighted MR imaging in a xenograft tumor model.
Nucleic acids
Abnormalities in gene expression cause cancer, providing
tumor cells with essential alterations in aspects of cell
physiology such as apoptosis, metastatic potential, angio-
genesis, and growth/anti-growth signaling [18]. Increased
understanding of gene expression and the development of
techniques to detect expression levels have led to new
means of early cancer diagnosis and therapy. During the
past decade, increased attention has been given to DNA,
mRNA, and miRNA, which are present at high concentra-
tions in patients with cancer compared with healthy indi-
viduals. Abnormally expressed miRNAs have been
increasingly utilized because of their fundamental role in
cancer metastasis [51]. Well-tailored, activatable nano-
structures for tumor detection and suppression have been
designed to deliver oligonucleotides to cells without being
degraded by endogenous nucleases. For example, Kim et
al. [42] reported a hyaluronic-based nanocontainer with
miR-34a beacons that could be used to detect breast
cancer [42]. Upon injection, the nanocontainers bind to
CD44 receptor and become internalized by endosomes,
where they are subsequently disrupted by the low pH,
leading to the release of miR-34a beacons into the cyto-
plasm. The miR-34a beacons contain a linear oligo-
nucleotide that is complementary to miR-34a. That
Fig. 7 a Schematic illustration of the formation of DOX-loaded MSN@MnO2 and GSH-triggered drug release in cancer cells. b Fluorescence images of
HepG2 cells incubated with DOX-loaded MSN@MnO2 for 3 h. c Viability of HepG2 cells after being treated by free DOX, MSN, MSN@MnO2, or DOX-loaded
MSN@MnO2 for 48 h. NPs = nanoparticles. Reproduced with permission from ref. 53; Copyright 2015 Wiley-VCH
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oligonucleotide is conjugated to Cy5.5 dye and is also
annealed to a shorter oligonucleotide that is conjugated
to black-hole quencher 2 (BHQ-2) as a fluorescent ac-
ceptor. When the beacons are released into the cyto-
plasm (Fig. 8), miR-34a binds to the complementary
sequence, displacing the BHQ-2 and thus turning on
the signal. The researchers successfully detected and
created images of miR-34a in breast cancer animal
models. Shi et al. [68] utilized cell-membrane protein
kinase-7 (PTK7) to activate an aptamer probe [68]. The
activatable aptamer probe (AAP) consisted of three frag-
ments: a cancer-targeted aptamer sequence (A-strand), a
poly T linker (T-strand), and a short DNA sequence
(C-strand) complementary to a part of the A-strand
with a fluorophore and quencher attached to both
termini. The hybridization of the A-strand to the C-
strand resulted in a hairpin conformation that holds
the fluorophore and quencher together, keeping the
nanostructure in a quenched state. When the AAP
binds the cell-membrane protein receptor, spontaneous
conformational reorganization occurs, separating the
fluorophore from the quencher and switching the signal
on. The AAPs successfully displayed enhanced contrast in
vitro and in vivo compared with ‘always-on’ probes,
facilitating sensitive detection of early-stage cancer.
Cancer-specific mRNAs have been utilized to detect
tumor progression. Li et al. [49] utilized multiple mRNA
targets to improve the accuracy of cancer detection in
single-marker assays [49]. They synthesized a multicolor
fluorescent nanoprobe consisting of gold nanoparticles
functionalized with three short, dye-terminated reporter se-
quences via a gold-thiol linkage. The gold nanoparticles
quench the fluorescence of the dye. Upon RNA or DNA
hybridization with a more stable complementary sequence,
the reporter sequence is released, turning the fluorescent
signal on. The researchers successfully distinguished be-
tween cancer cells and normal cells and reported changes
in the expression levels of tumor-related mRNAs.
Limitations of stimuli-responsive nanoparticles
Stimuli-responsive nanosystems have seen tremendous
growth in the past few decades. Their efficacy for cancer
detection and therapy is undeniable; however, certain
challenges still exist that need to be addressed and may
vary from one patient to another. The pH-activated
nanosystems that disrupt the lysosomal membrane may
lead to the release of lysosomal enzymes into the cell
cytoplasm, which can cause autophagy and cell death.
Also, the release of payload inside the lysosomes may
lead to denaturation, causing significant loss of efficacy.
Fig. 8 a Schematic illustration of the miR-34a beacon delivery system for targeted intracellular recognition of miR-34a based on HA-coated
nanocontainers that encapsulate the miR-34a beacons (bHNCs); consecutive processes of (i) binding to CD44 receptors, (ii) internalization into
an endosome, (iii) disassembly of bHNCs leading to the destabilization of endosome membranes after pH reduction, and (iv) final displacement of the
miR-34a beacons from the HNCs permitting transport into the cytoplasm. b In vivo and ex vivo imaging of miR-34a in an orthotopic breast cancer
model. In vivo optical fluorescence images of MDA-MB-231 tumor-bearing mice after the intravenous injection of bHNCs, bPNCs, and bHNCs after free
HA treatment (10 mg/mL of HA in PBS per animal) at various time intervals. Tumor regions are indicated by a white dashed boundary. c Total photon
counts in tumor regions after injection of bHNCs, bPNCs, and bHNCs after free HA treatment (miR-34a beacon concentration = 5 nmol). d Ex vivo
optical fluorescence images of tumors excised 1-h post injection of bHNCs, bPNCs, and bHNCs after free HA treatment. The intensity maps on the
fluorescence images are displayed as the normalized photon counts (NC) per point with laser power (5.0 μW) and integration time (0.4 s).
Reproduced with permission from ref. 42; Copyright 2012 ACS Publications
Kang et al. Journal of Biological Engineering  (2017) 11:13 Page 10 of 12
Enzyme-activated systems also face various challenges.
Enzyme dysregulation in various diseases and at various
stages of the same disease needs to be studied extensively
for eventual clinical translation. Overlapping substrates
between closely related enzymes can cause nonspecific up-
take or cleavage, resulting in systemic toxicity. Nucleic
acid-activated nanoparticles have a major drawback based
on the fact that protein upregulation is not always related
to nucleic acid upregulation in cancer, which may lead to
untrustworthy conclusions. Hypoxia and oxidative stress
is present at elevated levels in all cancer types. However,
high levels of ROS may cause activation of various
signaling pathways leading to cell death.
Conclusions and perspectives
We reported a general overview of the role of nanoparti-
cles in the efficient delivery of drugs, genes, contrast
agents, and other functional molecules for cancer imaging
and therapy via specific targeting and selective activation in
the cellular niche. Tumor microenvironment-activatable
nanosystems with nanocarriers acting as ‘homing devices’
loaded with therapeutic contrast/therapeutic agent and
coated with responsive polymers or probes provide new in-
sights into cancer therapy by demonstrating high specificity
and sensitivity with minimal degradation or background
signal. The successful translation of activatable nanosys-
tems into clinical trials will change the very foundation of
tumor theragnostics. Their controlled release, specific tar-
geting, and biocompatibility will make them an important
component of personalized therapy in the near future.
Nevertheless, some limitations still exist, and more data is
needed to translate the results obtained in animal models
into applications in humans. The experimental models in
humans are not yet standardized and much more hetero-
geneous than animal models because of high heterogeneity
in blood flow, which often makes comparison of results
troublesome. In vivo systems are complex, and studies and
regulations are essential to ensure the biocompatibility of
nanocarriers in humans. We anticipate that many of the
current problems will be resolved in the near future, and
we expect that much of the current research will be trans-
lated into clinical applications.
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